Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

This study tests the combination of two drugs — mosunetuzumab (a bispecific antibody that helps the immune system attack cancer cells) and polatuzumab vedotin (an antibody linked to a chemotherapy drug) — in patients with follicular lymphoma (a slow-growing type of blood cancer) that has returned or stopped responding to treatment. **You may be eligible if...** - You are 18 or older with confirmed grade 1–3a follicular lymphoma - Your lymphoma has relapsed or is not responding after at least one prior treatment - Your tumor is CD20-positive (a protein present on most lymphoma cells) - You are in good to moderate health (ECOG 0–2) **You may NOT be eligible if...** - You currently have diffuse large B-cell lymphoma or grade 3b follicular lymphoma - You have active autoimmune disease requiring systemic treatment - You have untreated or active central nervous system lymphoma Talk to your doctor to see if this trial is right for you.